UCB Launches Neupro® in the U.S. to treat Parkinson’s Disease and Restless Legs Syndrome
Brussels, Belgium and Atlanta, GA – July 16, 2012 – UCB announced today that Neupro® (Rotigotine Transdermal System) is now available in U.S. pharmacies. Neupro® was approved by the U.S Food and Drug Administration in April to treat the signs and symptoms of early and advanced stage idiopathic Parkinson’s disease and moderate-to-severe primary Restless Legs Syndrome. Click here to read more.
Click for a printer friendly version